サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405866

糖尿病網膜症の市場規模、シェア、動向分析レポート：タイプ別、管理別、地域別、セグメント予測、2024年～2030年

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-Proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region, & Segment Forecasts, 2024-2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
糖尿病網膜症の市場規模、シェア、動向分析レポート：タイプ別、管理別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月15日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病網膜症市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の糖尿病網膜症の市場規模は、2030年までに137億7,000万米ドルに達すると予測され、2024年から2030年までのCAGRは6.43％で拡大すると予測されています。

糖尿病有病率の上昇、高齢者人口の増加、糖尿病による失明有病率の増加が、予測期間中の市場成長を促進すると予測される主な要因です。市場の成長は、糖尿病の管理とケアに関する意識の高まりと新製品の発売によってさらに促進されます。糖尿病網膜症は、網膜の血管の損傷によって引き起こされ、ほとんどの場合、目のかすみや視力低下につながります。

高齢化、肥満、不健康なライフスタイルによる糖尿病有病率の増加が市場の成長に寄与しています。肥満は糖尿病を引き起こす主な要因です。WHOによると、2021年には世界で18歳以上の成人の約39％が過体重、13％が肥満でした。肥満に加えて、糖尿病も世界的にますます蔓延しています。国際糖尿病連合（IDF）の推計によると、2021年には5億3,700万人の成人（20歳から79歳）が糖尿病を患っており、2040年には6億4,200万人に増加すると予想されています。IDFはまた、糖尿病の有病率は世界的に増加しており、低・中所得国で最も高い増加が見られると報告しています。2021年に糖尿病患者数が最も多い地域は、アジア太平洋（1億6,700万人）、南アジア（8,800万人）、欧州（5,900万人）です。

高齢者の糖尿病は死亡率の上昇や機能的状態の低下に直結するため、高齢者人口の増加は糖尿病流行の重要な促進力となっています。WHOによると、2050年までに高齢者の80％が低・中所得国に住むと予想されています。人口の高齢化率は、過去に比べてかなり高くなっています。2020年には、60歳以上の高齢者の数が5歳未満の子どもを上回りました。2015年から2050年の間に、世界人口に占める60歳以上の高齢者の割合は12%から22%へとほぼ倍増します。

糖尿病網膜症市場レポートハイライト

  • 2023年のタイプ別シェアは、非増殖糖尿病網膜症が最大です。糖尿病歴10年未満の患者数が多いことが、このセグメントの市場規模を大きくしました。
  • 抗VEGF薬セグメントは、2023年に管理別で最大のシェアを占めました。早期診断と軽度から中等度の非増殖性DR治療におけるこれらの薬剤の高い適用性が、セグメント成長を導く主要因の一つです。
  • アジア太平洋市場は、予測期間中に最も高いCAGRで成長すると予想されます。同地域の人口の多さ、糖尿病有病率の高さ、高齢者人口の増加が市場を強化する可能性が高いです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 糖尿病網膜症の市場変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 糖尿病網膜症市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 糖尿病網膜症市場：タイプの推定・動向分析

  • タイプ市場シェア、2023年・2030年
  • セグメントダッシュボード
  • タイプ別の世界の糖尿病網膜症市場の見通し
  • 以下の市場規模、予測および動向分析、2018年～2030年
    • 増殖性糖尿病網膜症
    • 非増殖性糖尿病網膜症

第5章 糖尿病網膜症市場：管理推定・動向分析

  • 管理市場シェア、2023年・2030年
  • セグメントダッシュボード
  • 管理見通し別の世界の糖尿病網膜症市場
  • 以下の市場規模、予測および動向分析、2018年～2030年
    • 抗VEGF
    • ステロイド眼内注射
    • レーザー手術
    • 硝子体手術

第6章 糖尿病網膜症市場：地域推定・動向分析

  • 地域市場シェア分析、2023年・2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測・動向分析、2018年～2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Bayer AG
    • ABBVIE INC.
    • Novartis AG
    • Oxurion NV
    • Sirnaomics
    • Alimera Sciences
    • Ampio Pharmaceuticals Inc.
    • BCNPeptides
    • Kowa Company Ltd.
    • Genentech, Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 5 U.S. refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 6 U.S. refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 7 Canada refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 8 Canada refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 9 Europe refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 12 Germany refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 13 Germany refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 14 UK refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 15 UK refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 16 France refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 18 Italy refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 20 Spain refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 22 Denmark refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 24 Sweden refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 26 Norway refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 31 China refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 32 China refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 33 Japan refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 34 Japan refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 35 India refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 36 India refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 37 South Korea refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 38 South Korea refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 39 Australia refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 40 Australia refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 41 Thailand refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Thailand refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 43 Latin America refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 44 Latin America refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 45 Brazil refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 46 Brazil refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 47 Mexico refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 48 Mexico refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 49 Argentina refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 50 Argentina refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 51 MEA refurbished MRI systems market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 53 MEA refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 54 South Africa refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 55 South Africa refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 58 UAE refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 59 UAE refurbished MRI systems market, by management, 2018 - 2030 (USD Million)
  • Table 60 Kuwait refurbished MRI systems market, by technology, 2018 - 2030 (USD Million)
  • Table 61 Kuwait refurbished MRI systems market, by management, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Refurbished MRI systems market: market outlook
  • Fig. 14 Refurbished MRI systems competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Refurbished MRI systems market driver impact
  • Fig. 20 Refurbished MRI systems market restraint impact
  • Fig. 21 Refurbished MRI systems market strategic initiatives analysis
  • Fig. 22 Refurbished MRI systems market: Type movement analysis
  • Fig. 23 Refurbished MRI systems market: Type outlook and key takeaways
  • Fig. 24 Proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
  • Fig. 25 Non-proliferative diabetic retinopathy estimates and forecast, 2018 - 2030
  • Fig. 26 Refurbished MRI systems Market: Management movement Analysis
  • Fig. 27 Refurbished MRI systems market: Management outlook and key takeaways
  • Fig. 28 Anti-VEGF market estimates and forecasts, 2018 - 2030
  • Fig. 29 Laser surgery market estimates and forecasts,2018 - 2030
  • Fig. 30 Vitrectomy market estimates and forecasts,2018 - 2030
  • Fig. 31 Global refurbished MRI systems market: Regional movement analysis
  • Fig. 32 Global refurbished MRI systems market: Regional outlook and key takeaways
  • Fig. 33 Global refurbished MRI systems market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2018 - 2030
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2018 - 2030
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2018 - 2030
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 87 Mexico
  • Fig. 88 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 101 Market share of key market players - Diabetic retinopathy market
目次
Product Code: 978-1-68038-466-6

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market size is anticipated to reach USD 13.77 billion by 2030 and is anticipated to expand at a CAGR of 6.43% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are the major factors anticipated to boost market growth over the forecast period. Growth in the market is further propelled by the increasing awareness about diabetes management & care and new product launches. Diabetic retinopathy is caused by damage to the blood vessels in the retina, which leads to blurred vision and vision loss in most cases.

The increase in prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to WHO, in 2021, around 39% of adults aged 18 years and above were overweight, and 13% were obese worldwide. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimated l537 million adults (aged 20 to 79 years) were living with diabetes in 2021, which is expected to rise to 642 million by 2040. The IDF also reports that the prevalence of diabetes is increasing globally, with the highest increases witnessed in low- and middle-income countries. In 2021, the regions with the highest number of adults living with diabetes were the Western Pacific (167 million), South Asia (88 million), and Europe (59 million).

The rising geriatric population is a significant driver of the diabetes epidemic, as diabetes in older people is directly linked with higher mortality and reduced functional status. According to WHO, 80% of older people are expected to live in low- and middle-income nations by 2050. The population is aging at a considerably higher rate than in the past. In 2020, the number of persons aged 60 years and more will outnumber children under the age of 5 years. Between 2015 and 2050, the proportion of the global population aged over 60 years will nearly double, from 12% to 22%.

Diabetic Retinopathy Market Report Highlights:

  • Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2023. The presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
  • Anti-VEGF segment accounted for the largest share, by management, in 2023. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
  • The Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Management
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Management outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of diabetes
      • 3.2.1.2. Growing geriatric population
      • 3.2.1.3. Increasing prevalence of blindness due to diabetes
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of accurate diagnosis
      • 3.2.2.2. Adverse effect on treatment
  • 3.3. Diabetic Retinopathy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Diabetic Retinopathy Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Proliferative Diabetic Retinopathy
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-proliferative Diabetic Retinopathy
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

  • 5.1. Management Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Diabetic Retinopathy Market by Management Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Anti-VEGF
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Intraocular Steroid Injection
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Laser Surgery
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Vitrectomy
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Bayer AG
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. ABBVIE INC.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Novartis AG
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Oxurion NV
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Sirnaomics
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Alimera Sciences
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Ampio Pharmaceuticals Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. BCNPeptides
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Kowa Company Ltd.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Genentech, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives